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The ability to alter antigen specificity by T-cell receptor (TCR) or chimeric antigen 
receptor (CAR) gene transfer has facilitated personalized cellular immune therapies in 
cancer. Inversely, this approach can be harnessed in autoimmune settings to atten-
uate inflammation by redirecting the specificity of regulatory T cells (Tregs). Herein, 
we demonstrate efficient protocols for lentiviral gene transfer of TCRs that recognize 
type 1 diabetes-related autoantigens with the goal of tissue-targeted induction of 
antigen-specific tolerance to halt β-cell destruction. We generated human Tregs 
expressing a high-affinity GAD555–567-reactive TCR (clone R164), as well as the lower 
affinity clone 4.13 specific for the same peptide. We demonstrated that de novo Treg 
avatars potently suppress antigen-specific and bystander responder T-cell (Tresp) 
proliferation in vitro in a process that requires Treg activation (P < 0.001 versus unac-
tivated Tregs). When Tresp were also glutamic acid decarboxylase (GAD)-reactive, 
the high-affinity R164 Tregs exhibited increased suppression (P <  0.01) with lower 
Tresp-division index (P < 0.01) than the lower affinity 4.13 Tregs. These data demon-
strate the feasibility of rapid expansion of antigen-specific Tregs for applications in 
attenuating β-cell autoimmunity and emphasize further opportunities for engineering 
cellular specificities, affinities, and phenotypes to tailor Treg activity in adoptive cell 
therapies for the treatment of type 1 diabetes.
Keywords: type 1 diabetes, regulatory T cells, T cell receptor, avidity, suppression mechanisms, adoptive cellular 
therapies, antigen-specific T cells, glutamic acid decarboxylase 65
inTrODUcTiOn
T-cell receptor (TCR) transgenic regulatory T cells (Tregs) may represent a promising personalized 
treatment for T-cell-mediated autoimmune diseases such as type 1 diabetes. A curative therapy that 
targets the underlying immunological cause of disease to restore antigen-specific immunological 
tolerance represents an essential objective for the preservation of β-cell mass and function in the 
treatment of type 1 diabetes (1). Non-antigen-specific therapies involving hematopoietic stem 
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cell transplantation combined with T-cell depletion, via 
high-dose anti-thymocyte globulin (ATG) or fludarabine, 
plus immunomodulation with cyclosporine and granulocyte-
colony stimulating factor (G-CSF) have been shown to 
preserve β-cell function (2, 3), but the risks associated with 
these aggressive protocols preclude common clinical use. 
Comparatively, non-specific polyclonal immunotherapies, 
including immunoregulatory or depleting agents [e.g., ale-
facept (human LFA-3/IgG1-Fc fusion protein), teplizumab or 
otelixizumab (anti-CD3), and rituximab (anti-CD20)], have 
been better tolerated and offered some temporary efficacy but 
not long-term induction of tolerance (4–10). Until recently, 
most antigen-specific tolerance induction efforts have involved 
mucosal or peripheral administration of autoantigen(s), but 
thus far, such attempts have yielded limited efficacy in only a 
subset of patients, again with no indication for long-term toler-
ance induction (11, 12). Indeed, a safe treatment that controls 
persistent immune memory and induces long-term tolerance 
is needed.
Islet cell antigen-reactive Tregs, isolated from BDC2.5 TCR 
transgenic mice, could be expanded in  vitro, and following 
adoptive transfer, migrate to the pancreatic draining lymph 
node/nodes (13). These Treg prevent and reverse autoimmune 
diabetes in non-obese diabetic (NOD) mice (14). In contrast, 
Tregs isolated and expanded from GAD286 TCR transgenic 
mice could suppress responder T cells (Tresp) in vitro but did 
not proliferate in vivo after transfer into recipient animals (14). 
Moreover, expression of cognate autoantigen is required for 
efficient trafficking of Tregs to the target organ and suppression 
of diabetes in NOD mice (15). These preclinical data support the 
notions that autoantigen-specific Tregs may offer an important 
therapy for type 1 diabetes, but also that intrinsic factors such 
as TCR specificity and/or avidity may play an important role in 
determining the capacity for immunomodulation and efficacy. 
The need for continued autoantigen expression by the host 
may render insulin-reactive TCRs less effective in patients with 
long-standing type 1 diabetes and support a need to investigate 
additional, potentially bystander, TCRs specific for additional/
alternative autoantigen targets such as glutamic acid decar-
boxylase (GAD). Moreover, antigen localization, density, and 
persistence in β-cells along with risk of effector cell reprogram-
ming support the use of alternative TCRs (16).
Genetically modified T cells with TCRs specific for tumor or 
viral antigens have become a valuable tool for the treatment of 
certain cancers or infections in humans (17–19). We previously 
demonstrated successful HLA class I-restricted TCR gene trans-
fer in human Tregs using a high-affinity model receptor specific 
for the melanoma antigen tyrosinase presented by HLA-A*02:01 
(20). We also generated a murine form of these tyrosinase-specific 
Tregs, and when transferred in  vivo, the cells were capable of 
suppressing anti-tumor immunity in murine tumor models (20). 
This prompted us to ask whether candidate TCRs specific for 
type 1 diabetes-related autoantigens could be used to generate 
regulatory TCR avatars for human therapy.
Two TCR clones (R164 and 4.13) specific for the same β-cell 
peptide (GAD555–567) presented by HLA-DR4, but with different 
binding affinities, have been identified from the peripheral blood 
of subjects with or at-risk for T1D (21–23). Indeed, we recently 
identified T cells expressing the TCR β-chain complementarity 
determining region (CDR3β) of the GAD 4.13 clone from tissues 
of seven organ donors with type 1 diabetes, including the pan-
creatic islets of one type 1 diabetes subject. Interestingly, for one 
donor with long-standing disease, the TCR CDR3β was highly 
enriched in the pLN (>25% of all productive sequences), repre-
senting the most prevalent clone in both the Treg and conventional 
CD4+ T-cell (Tconv) populations (24). Interestingly, 4.13 TCR 
transgenic HLA-DR4 mice were reported to contain a mixture 
of Th1 and Tr1 cells capable of producing IL-10 (21). Conversely, 
R164 TCR transgenic HLA-DR4 mice exhibited greater thymic 
negative selection, and the T cells that escaped the thymus were 
skewed toward a Th1 phenotype (21). These observations support 
the notion that TCR avidity may impart important functional 
distinctions.
In a recent report by Ali et  al., human CD4+ T  cells were 
engineered to express the R164 TCR clone, and importantly, 
when administered to NSG-Ab0 DRB*04:01 mice, these R164 
cells established long-term engraftment and islet infiltration, up 
to 12 weeks, without graft versus host disease (GvHD) (25). The 
creation of these autoreactive T-cell avatars presents the exciting 
possibility of autologous Treg therapy for type 1 diabetes with 
the benefit of antigen specificity to potentially enhance Treg traf-
ficking to the target organ and associated draining lymph nodes. 
These antigen-specific Tregs would likely represent a significant 
improvement upon autologous polyclonal Treg therapy, which 
has already been shown to be safe for use in human subjects 
(26, 27). Indeed, antigen-specific Tregs offer the potential for 
long-term tolerance to the target antigen and possibly, to other key 
β-cell epitopes via bystander suppression and infectious tolerance 
(14, 28). To expand on these efforts, we generated primary human 
Tregs expressing the two GAD555–567-reactive TCR clones (R164 
and 4.13), and investigated the pre-transfer conditions needed 
to optimize suppressive activity for potential use in adoptive cell 
therapy.
research Design anD MeThODs
Design and synthesis of lentiviral 
constructs
Lentiviral vectors were generated to express TCR clones 4.13 
and R164, both of which react to GAD555–567 (21, 25) (Table 1). 
Equimolar expression of TCR α- and β-chains was achieved by 
inclusion of a multicystronic P2A element, followed by a T2A 
element and the reporter, enhanced green fluorescent protein 
(eGFP). The constructs were cloned into pCNFW lentiviral 
vectors with expression driven by a cytomegalovirus promoter 
as previously described (25) (Figure  1A). Lentiviral vectors 
containing the Melan-A reactive TCR clone melanoma antigen 
recognized by T cells 1 (MART-1) were generated as previously 
described (29) (Table 1).
lentivirus Production
Lentiviral vectors were generated as described (20). Briefly, 
55  µg of lentiviral vector and 18.3  µg of each helper plasmid 
TaBle 1 | T-cell receptor (TCR) clone information.
Tcr (iMgT) Tra gene TrB gene pMhc restriction source
s. no. clone V J cDr3 aa sequence V D J cDr3 aa sequence hla antigen
1 5 TRAV21 TRAJ6 CAVKRTGGSYIPTF TRBV11-2 TRBD1 TRBJ2-2 CASSSFWGSDTGELFF DQ8 InsB (9–23) Roep, personal 
communication
2 GSE.20D11a TRAV12-3 TRAJ4 CAILSGGYNKLIF TRBV02-01*01 TRBD02-01 TRBJ02-05*01 CASSAETQYF DQ8 InsB (9–23) (30)
3 GSE.6H9a TRAV26-1 TRAJ40 CIVRVDSGTYKYIF TRBV7-2 TRBD2 TRBJ2-1 CASSLTAGLASTYNEQFF DQ8/
DQ8-trans
InsB (9–23) (30)
4 T1D#3 C8 TRAV17 TRAJ23 CATDAGYNQGGKLIF TRBV5-1 TRBD2 TRBJ1-3 CASSAGNTIYF DQ8 InsB (9–23) (31)
5 T1D#10 C8 TRAV12-3 TRAJ26 CATAYGQNFVF TRBV4-1 TRBD2 TRBJ2-2 CASSRGGGNTGELFF DQ8 InsB (9–23) (31)
6 PM1#11 TRAV35*02 TRAJ54*01 CAGHSIIQGAQKLVF TRBV5-1*01 TRBD2*02 TRBJ2-1*01 CASGRSSYNEQFF DRB1*03:01 GAD (339–352) (32)
7 MHB10.3 TRAV4*01 TRAJ27*01 CLVGDSLNTNAGKSTF TRBV29-1*01 TRBD2*01 TRBJ2-2*01 CSVEDRNTGELFF DRB1*03:01 InsB (11–30) (33)
8 SD32.5 TRAV26-1*01 TRAJ23*01 CIVRVSSAYYNQGGKLIF TRBV27*01 TRBD2*01 TRBJ2-3*01 CASSPRANTDTQYF DRB1*04:01 InsA (5–21) (34)
9 SD52.c1 TRAV4*01 TRAJ27*01 CLVGDSLNTNAGKSTF TRBV27*01 TRBD1*01 TRBJ1-5*01 CASSWSSIGNQPQHF DRB1*04:01 PPI (C18–A1) (34)
10 R164 TRAV19*01 TRAJ56*01 CALSEEGGGANSKLTF TRBV05-01*01 TRBD02-01*01 TRBJ01-06*01 CASSLAGGANSPLHF DRB1*04:01 GAD (555–567) (23)
11 4.13 TRAV19*01 TRAJ44*01 CALSENRGGTASKLTF TRBV05-01*01 TRBD01-01*01 TRBJ01-01*01 CASSLVGGPSSEAFF DRB1*04:01 GAD (555–567) (21)
12 1E6 TRAV12-3 TRAJ12 CAMRGDSSYKLIF TRBV12-4 TRBD2 TRBJ2-4 CASSLWEKLAKNIQYF A*02-01 PPI (15–24) (35)
13 D222D TRAV17*01 TRAJ36*01 CAVTGANNLFF TRBV19*01 TRBD1*01 TRBJ2-2*01 CASSIEGPTGELFF A*02-01 ZnT8 (186–194) Patent 
WO2017046335 
A1
14 32 TRAV12-1 TRAJ48*01 CVVNILSNFGNEKLTF TRBV20 TRBD01-01*01 TRBJ2-01*01 CSASRQGWVNEQFF A*02-01 IGRP (265–273) (36)
15 MART-1 TRAV12-2 TRAJ23 CAVNFGGGKLIF TRBV6-4 TRBD2 TRBJ1-1 CASSLSFGTEAFF A*02-01 Melan-A (27–35) (37)
For the experiments described herein, T cells were transduced to express TCR clones 4.13 or R164, which were first identified from the peripheral blood or pancreas of a type 1 diabetes patient or an autoantibody positive subject 
at risk for T1D. CD8+ T cells were transduced to express melanoma antigen recognized by T cells 1 (MART-1) TCR. Remaining TCR clones [sourced from the international ImMunoGeneTics information system®, IMGT.org (IMGT)] 
listed are those with known reactivities to type 1 diabetes-related autoantigen peptides with which we can generate lentivirus constructs to create additional Treg avatars. TCRα (TRA) and TCRβ (TRB) V, D, and J genes as well as 
complementarity determining region 3 (CDR3) amino acid (AA) sequence, HLA restriction, and antigen target are listed for each clone.
aIntra-islet source material.
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FigUre 1 | Verifying transfection and activation of Jurkat cells expressing T-cell receptor (TCR) clones. (a) Lentiviral constructs were designed containing the TCR 
α- and TCR β-chain genes (TRA and TRB, respectively) for known glutamic acid decarboxylase (GAD)-reactive clones (R164 and 4.13, additional clone information 
is listed in Table 1). The TRA and TRB coding regions were joined by a multicystronic P2A element, and TRB was linked by a multicystronic T2A element to an 
enhanced green fluorescent protein (eGFP) reporter. Amino-acid sequences for the complementarity determining region 3 (CDR3) are shown for both clones.  
(B) Jurkat T cells were untransduced (Mock; top), transduced with lentivirus expressing the R164 TCR (middle), and lentivirus expressing the 4.13 TCR (bottom), 
and expression was confirmed by flow cytometry. Double positivity for TCR Va12.1 and Vβ5.1, which is comparable between both clones, and eGFP indicates 
successful transduction. Untransduced cells were negative for both markers. (c) Mock (top), 4.13 (middle), and R164 (bottom) TCR-transduced cells were 
unstimulated (black), stimulated with plate bound anti-CD3 (p.b. α-CD3, blue), irrelevant antigen influenza hemagglutinin (HA306–318, orange), or cognate antigen 
(GAD555–567, green). TCR expression (left panels) was comparable across all unstimulated, HA-stimulated, and GAD-stimulated cells, and p.b. α-CD3 stimulation 
induced TCR downregulation. p.b. α-CD3 stimulation also induced the highest level of CD69 expression (right panels), and unstimulated cells exhibited low CD69 
expression. These observations were comparable across mock, R164, or 4.13 transduced cells.
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were co-transfected in 293T cells using TransIT-2020 transfec-
tion reagent (Mirus, Madison, WI, USA). Supernatants were 
collected 72  h after transfection, filtered through a 0.45-µm 
filter, and concentrated by ultracentrifugation at 198,000 ×  g 
for 1.5 h.
subject enrollment and T-cell isolation
Healthy control blood donors provided written informed 
consent prior to inclusion in the study in accordance with the 
Declaration of Helsinki and according to Institutional Review 
Board-approved protocols at the University of Florida (Protocol 
no. IRB201600092) and the University of Colorado Denver 
(Protocol no. COMIRB92-292). T cells where enriched by nega-
tive selection from whole blood by Ficoll-Paque density gradient 
in combination with a total T-cell enrichment cocktail by follow-
ing manufacturer’s instructions (Catalog no. 15061, STEMCELL 
Technologies, Cambridge, MA, USA). Cells were stained with 
fluorescently labeled antibodies [CD4-PB (clone RPA-T4), 
CD8-APC.H7 (SK1), CD25-APC (BC96), CD127-PE (A019D5), 
and CD45RA-PE-Cy7 (HI100)]. CD4+CD25+CD127lo/− 
Tregs, CD4+CD25−CD127+CD45RA+ naïve Tconv cells, and 
CD8+CD45RA+ naïve CD8+ T cells were purified by fluorescence-
activated cell sorting (FACS) using a BD FACSAria III (BD 
Biosciences, San Jose, CA, USA).
5Yeh et al. Designer Tregs for the Treatment of Human T1D
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lentiviral Transduction (lV TD) of human  
T cells
Jurkat Cells
Human Jurkat T  cells were plated at 2  ×  105  cells/well in a 
24-well plate and transduced in the presence of protamine sulfate 
(8  µg/mL; Sigma-Aldrich, St. Louis, MO, USA). Transgene 
expression was assessed 72 h post-transduction by flow cytom-
etry (Figure 1).
Primary Human T Cells
Primary human T cells were transduced as previously described 
(3). Briefly, FACS-purified CD4+ T  cells (total), Tregs, naïve 
Tconv cells, and naïve CD8+ T cells were plated at 2.5 × 105 cells/
well in a 24-well plate. Total CD4+ T cells, naïve Tconv, and CD8+ 
T cells were activated with anti-CD3 and anti-CD28 dynabeads 
(Catalog no. 11161D, ThermoFisher Scientific, Waltham, MA, 
USA), while Tregs were expanded with anti-CD3 and anti-CD28 
conjugated microbeads (Catalog no. 130-091-441, Miltenyi 
Biotec, San Diego, CA, USA) according to the manufacturer’s 
instructions. After 48 h of activation, cells were supplied with 
protamine sulfate (8 µg/mL) and transduced with 3 TU/cell of 
lentivirus for TCR expression followed by spinoculation. Total 
CD4+ T cells were supplied IL-2 (30 IU/mL) every 2–3 days and 
restimulated with the HLA-DR4 (DRB1*04:01) expressing K562 
artificial antigen-presenting cell (aAPC) line and GAD555–567 
peptide on day 9 and day 16 for serial activation (Figure  2). 
For T-cell subsets, IL-2 (300  IU/mL for Treg; 20  IU/mL 
for Tconv; 100  IU/mL for CD8+ T  cells) was supplied every 
1–2 days during expansion (Figure 3). K562 aAPCs were kindly 
provided by Drs. James Riley and Bruce Levine (University of 
Pennsylvania).
Flow cytometry
Cells were first stained with live/dead near-IR (Invitrogen) 
followed by fluorescently labeled antibodies specific for the fol-
lowing surface markers: CD4-PB (clone RPA-T4), CD69-BV711 
(FN50), TCR Vα12.1-Alexa Fluor 647 (6D6.6), TCR Vβ5.1-PE 
(IMMU 157), OX40-APC (ACT35), and CD25-PE (BC96). 
The TCR Vα12.1 monoclonal antibody was labeled with Alexa 
Fluor 647 using Zenon labeling kit (ThermoFisher Scientific, 
Waltham, MA, USA) before staining. Intracellular FOXP3 was 
stained using a FOXP3-Alexa Fluor 488 (206D) antibody with a 
FOXP3/transcription factor staining kit (Catalog no. 00-5523-
00, ThermoFisher Scientific, Waltham, MA, USA) according 
to the manufacturer’s instructions. Flow cytometry data were 
collected using an LSRFortessa (BD Biosciences) and analyzed 
with FlowJo software (Tree Star, Ashland, OR, USA).
Treg suppression assay
T-cell-receptor-redirected Tregs were FACS-purified based 
on their eGFP expression and tested for the ability to sup-
press polyclonal or TCR-transduced Tresp proliferation, as 
described previously (38). For suppression assays involving 
polyclonal Tresp, cells were stimulated with 2  µg/mL soluble 
anti-CD3 (clone Hit3a) and 1 µg/mL soluble anti-CD28 (clone 
28.2, BD PharMingen). Proliferation was determined by the 
incorporation of 3H-thymidine by pulsing cultures with 1 mCi 
of 3H-thymidine for the final 12–16 h of culture. Plates were har-
vested on a Packard FilterMate harvester and read on a Packard 
TopCount Scintillation & Luminescence Counter (Perkin Elmer; 
Waltham, MA, USA). Interferon-gamma (IFN-γ) was measured 
from the supernatant by ELISA. For suppression assays involv-
ing TCR-redirected Tresp, Tregs expressing the 4.13 TCR were 
stained with cell proliferation dye eFluor670 (5  µM; Catalog 
no. 65-0840-85, ThermoFisher Scientific, Waltham, MA, USA), 
whereas Tresp expressing the 4.13 TCR or a Melan-A27–35 reac-
tive MART-1 TCR were labeled with CellTrace Violet (5  µM; 
Catalog no. C34571, ThermoFisher Scientific, Waltham, MA, 
USA) following the manufacturer’s instructions. Tregs were 
plated in two-fold serial dilution, co-cultured with Tresp, and 
activated with the indicated peptide presented by irradiated 
CD3-depleted peripheral blood mononuclear cells (PBMCs) 
(HLA-DRB1*04:01 and A*02:01) for 3–4  days. Triplicate cul-
tures were pooled, harvested, stained with live/dead dye and for 
the surface markers, CD4 and CD8, and then analyzed by flow 
cytometry as described above. Proliferation was calculated by 
division and replication index of Tresp cells. Assay conditions 
are detailed in Table S1 in Supplementary Material.
statistical analysis
Data were analyzed by two-way analysis of variance (ANOVA) 
and graphs prepared using GraphPad Prism version 6 software 
(La Jolla, CA, USA).
resUlTs
Validation of Tcr expression and 
activation in human Jurkat cells
Two lentiviral constructs with identical backbone each contained 
the TCR α- and TCR β-chain genes (TRA and TRB, respectively) 
for the GAD555–567-reactive clones R164 or 4.13 followed by an 
eGFP reporter sequence as shown in Figure 1A. Multi-cystronic 
and equal molar expression of TCR α- and β-chains is achieved 
by including P2A and T2A elements between TRA, TRB, and the 
eGFP reporter. We used lentivirus carrying these constructs to 
transduce human Jurkat cells and express one of the two de novo 
TCRs. As expected, untransduced cells did not express eGFP, 
TCR α-chain V gene family 12.1 (TCRVα12.1), and TCR β-chain 
V gene family 5.1 (TCRVβ5.1), which are common to both R164 
and 4.13 clones (Figure 1B). Over 94% of Jurkat cells transduced 
with either the R164 or 4.13 TCR lentiviral construct were 
double positive for both TCRVα12.1 and Vβ5.1 with comparable 
mean fluorescence intensity (MFI) (Figure 1B). To verify stable 
transfection and antigen-specific activation of Jurkat cell lines, 
we stimulated mock (eGFP−), R164, and 4.13 transduced cells 
with K562 aAPCs loaded with cognate antigen (GAD555–567) and 
evaluated for TCR and CD69 expression levels. Positive and nega-
tive controls included stimulation of transduced cells with plate 
bound anti-CD3 or K562 aAPCs loaded with “irrelevant” antigen 
influenza hemagglutinin (HA306–318), respectively. Compared 
with unstimulated cells, anti-CD3 induced TCR downregulation 
concurrent with high expression of the activation marker CD69 
FigUre 2 | Serial activation increases transduction efficiency. (a) Primary CD4+ T cells remain untransduced (Mock) or transduced with lentivirus (LV TD) expressing 
T-cell receptor (TCR) clones 4.13 or R164 were activated with α-CD3/α-CD28 coated beads on day 0 (D0). Cells were restimulated with artificial APC (aAPCs; K562 
cell line expressing HLA-DR4) and GAD555–567 peptide for an additional two rounds on day 9 (D9) and day 16 (D16). IL-2 (30 IU/mL) was given every 2–3 days. 
Transduction efficiency was detected by fluorescence-activated cell sorting (FACS) every 4 days after stimulation (D4, D13, and D20). (B) TCR Vβ5.1 and enhanced 
green fluorescent protein (eGFP) reporter were assessed by flow cytometry on day 4 (D4, top), day 13 (D13, middle), and day 20 (D20, bottom). At each time point, 
a portion of untransduced cells were positive for TCR Vβ5.1, but no eGFP was observed. TCR Vβ5.1 and eGFP positivity was observed for 4.13 and R164 
transduced cells at each time point, and the proportion of dual positive cells increased with time.
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in each of the three cell lines (Figure 1C). GAD555–567 stimulation 
of both R164 and 4.13 cell lines resulted in high CD69 expres-
sion without TCR downregulation, whereas irrelevant antigen 
resulted in only modest upregulation of CD69, likely due to 
interaction with the costimulatory molecule, CD80 constituently 
expressed by the aAPCs (Figure 1C). These data support both 
surface receptor expression and activation in the presence of the 
cognate peptide presented by HLA-DR4.
FigUre 3 | Verification of T-cell receptor (TCR) overexpression and stability of transfected regulatory T cells (Tregs). (a) CD25+CD127lo/− Tregs (top and middle) and 
CD25lo/−CD127+CD4+CD45RA+ naïve conventional T cells (Tconv, bottom) were purified from adult peripheral blood by fluorescent-activated cell sorting (FACS). (B) 
Tregs were activated with α-CD3/α-CD28 coated beads on day 0 (D0). Lentiviral transduction (LV TD) was performed on day 2 (D2). Successfully transduced cells 
expressing enhanced green fluorescent protein (eGFP) were FACS-purified on day 19 (D19) for further analysis. (c) Treg (top) and Tconv cells (bottom) were 
untransduced (Mock; black), transduced with lentivirus containing the expression vector for the GAD-reactive TCR clone 4.13 (blue) or R164 (red), and eGFP 
expression among TCR transduced cells was confirmed by flow cytometry. (D) Mock (left), 4.13 (middle), and R164 (right) transduced Tregs (top) and Tconv cells 
(bottom) were stained for the TCRVα12.1 and TCRVβ5.1 chains that comprise the TCR clones 4.13 and R164, and overexpression was confirmed for TCR 
transduced cells. (e) Cell activation markers OX40 and CD25 were measured after co-culturing T cells with HLA-DR4 expressing K562 artificial antigen-presenting 
cells (aAPCs) loaded with GAD GAD555–567 peptide for 1 day. (F) The majority of Tregs in all conditions (non-transduced, 4.13, or R164) maintain FOXP3 expression 
(top left). Low frequency of FOXP3 expression was observed in Tconv (bottom left).
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Optimizing Tcr expression in Primary 
human cD4+ T cells
We next transduced primary human peripheral blood CD4+ 
T  cells to express the GAD-reactive 4.13 and R164 TCRs and 
assessed transduction efficiency. Cells were stimulated with 
anti-CD3/anti-CD28 coated beads on day 0, transduced on day 
2, and restimulated on days 9 and 16 with K562-DR4 aAPCs 
loaded with GAD555–567 peptide (Figure 2A). As expected, a por-
tion of untransduced cells expressed TCRVβ5.1 but not eGFP 
(Figure 2B). In addition, 35% of GAD 4.13 and 13% of GAD 
R164 cells were TCRVβ5.1+eGFP+ on day 4, and by day 20, 85 
and 71% of 4.13 and R164 cells, respectively, were double posi-
tive for TCRVβ5.1 and eGFP (Figure 2B) suggesting that serial 
activation resulted in enriched T-cell avatars.
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Tcr expression in Primary human 
regulatory and conventional T-cell 
subsets
CD4+CD25+CD127lo/− Tregs and CD4+CD25−CD127+CD45RA+ 
naïve Tconv were FACS-purified from peripheral blood 
(Figure 3A). We then generated primary human Tregs and Tconv 
expressing the GAD 4.13 and GAD R164 TCRs and expanded 
them with anti-CD3/CD28-coated beads for 19 days (Figure 3B). 
Again, compared with untransduced cells, 4.13 and R164 cells 
were confirmed to express high levels of eGFP (Figure  3C) as 
well as the Vα12.1 and Vβ5.1 chains of the GAD-reactive TCRs 
as measured by flow cytometry (Figure  3D). The activation 
markers OX40 and CD25 were upregulated on 4.13 and R164 
transduced Tregs compared with mock transduced Tregs 1 day 
post co-culture with HLA-DRB1*04:01 expressing K562 aAPC 
loaded with cognate peptide (Figure  3E). Similarly, OX40 was 
slightly upregulated on the surface of 4.13 and R164 transduced 
Tconv following aAPC-antigen activation, while CD25 upregula-
tion was more pronounced for R164 Tconv compared with 4.13 
Tconv (Figure  3E) (39). After transduction and anti-CD3/28 
stimulation, Tregs maintained FOXP3 positivity whereas Tconv 
cells showed low/intermediate expression of FOXP3 (Figure 3F) 
indicating transduction affected neither Treg differentiation nor 
development.
suppressive capacity of r164 and  
4.13 Treg avatars
The capacity to impact type 1 diabetes progression prior to 
symptomatic onset (i.e., in the context of multiple autoantibody 
positive high-risk individuals) or at the time of symptomatic 
disease will likely require the capacity to control a polyclonal 
memory T-cell response. Depletion of these cells is one potential 
approach but would require broad targeting resulting in a period 
of immunosuppression. We hypothesize that tissue targeting and 
dominant suppression of a broad repertoire by TCR-redirected 
Tregs may confer persistent tolerance. Therefore, we sought to 
understand if Treg avatars functionally suppress Tresp in an 
antigen-specific and/or bystander manner. We first demonstrated 
that LV TD does not affect Treg capacity to suppress polyclonal 
Tresp using well-described in vitro suppression assays (38). Both 
proliferation and IFN-γ production by polyclonal stimulated 
Tresp were comparable between R164, 4.13, and mock trans-
duced Treg groups (Figure S1 in Supplementary Material). Then, 
we assessed Treg suppressive capacity in both antigen-specific 
and bystander mechanisms with or without Treg activation 
(Figure  4A). At physiological ratios, Tregs showed excellent 
suppression of Tresp against cognate antigen by culturing both 
CD4+ Tresp and Tregs engineered to express a GAD-reactive 
TCR clone 4.13 and activated with cognate GAD555–567 peptide 
(Figures 4B,C, Ag-specific; Table S1 in Supplementary Material). 
Specifically, Tresp division was significantly blunted, and Treg 
percent suppression was significantly greater than in settings of 
bystander suppression (Figure 4C).
Importantly, CD8+ T cells are thought to drive type 1 diabetes 
pathogenesis in vivo through the direct killing of β-cells (40). We 
therefore sought to understand whether Treg avatars are capable 
of suppressing CD8+ T cells in a bystander manner in the islets 
or periphery. We tested the capacity of GAD-specific Tregs to 
suppress MART-1 CD8+ T cells recognizing the tumor antigen 
Melan-A, with or without Treg activation. While unactivated 
4.13 Tregs exhibited limited suppression of MART-1 CD8+ Tresp 
proliferation, GAD-activation of 4.13 Tregs resulted in signifi-
cantly reduced Tresp proliferation and increased suppression of 
MART-1 CD8+ Tresp (Figures 4B,C). This supports two notions: 
first, that Treg activation is required for functional suppression 
and second, that TCR transgenic Treg avatars are capable of both 
antigen-specific and bystander suppression.
Finally, we examined if TCR avidity affects Treg suppressive 
ability with the advantage of using two GAD555–567-reactive TCR 
clones, R164 and 4.13, where R164 exhibits higher avidity. Either 
GAD R164 or 4.13 Tregs were cultured with R164 CD4+ Tresp in 
the presence of peptide presented by CD3-depleted APCs from 
HLA-DRB1*04:01/A*02:01 individuals. We normalized the Treg 
suppression capacity against reporter eGFP MFI allowing us 
control for potential variation in TCR expression levels. Indeed, 
cells expressing the high-avidity R164 TCR were significantly 
more suppressive than cells expressing the lower avidity 4.13 
TCR (Figure 5). These data support the notion that Treg avatars 
engineered to receive a higher affinity signal through the TCR 
are more efficient suppressors of bystander T-cell responses. 
It remains to be investigated how costimulatory signals will 
impact suppressive activity, a notion that may be particularly 
important for assessing signaling through CAR-T vectors if 
expressed by Tregs.
DiscUssiOn
For tolerogenic adoptive cell therapy, autologous polyclonal Tregs 
can be expanded from peripheral blood which provides an attrac-
tive Treg source given the abundant cell numbers, allowing for 
repeat dosing if needed, and the safety associated with autologous 
cell therapy (26, 27). Concerns remain, however, regarding the lack 
of antigen specificity by administrating polyclonal Tregs. Indeed, 
Tregs have a highly diverse repertoire (24), which indicates the 
precursor frequency of autoreactive Tregs will likely be quite 
low in peripheral blood, especially considering that Tregs do not 
enrich to the extent that is observed for Tconv during conversion 
to effector T  cells and expansion. Hence, we expect polyclonal 
Treg therapy to confer potentially limited efficacy and trafficking 
to the pancreas or PLN to induce immunological tolerance for 
β-cell antigens. To address this, we utilized LV TD to generate 
primary human T-cell avatars expressing two GAD555–567-reactive 
TCRs (R164 and 4.13) originally identified from the peripheral 
blood of subjects with or at risk for type 1 diabetes (21–23). These 
clones, which differ by only 10 amino acids in TRAV and TRBV 
genes and only three amino acid charge differences in the CDR3 
region (Table  1), exhibit different binding affinities for their 
cognate antigen peptide (21).
Regulatory T cell avatars maintained FOXP3 positivity, indi-
cating that LV TD did not impair Treg stability. Functionally, 4.13 
Treg avatars effectively suppressed antigen-specific 4.13 CD4+ 
Tresp. Beyond this, 4.13 Treg avatars exhibited a moderate abil-
ity to suppress MART-1 CD8+ Tresp in a bystander suppressive 
FigUre 4 | Regulatory T-cell (Treg) suppression is optimal with activation. (a) Antigen-specific suppression by 4.13 Tregs was tested on 4.13 T-cell receptor (TCR) 
transduced conventional T cells (Tconv) in vitro (left). Bystander suppression by 4.13 Tregs was assessed on CD8+ T cells expressing the melanoma antigen 
recognized by T cells 1 (MART-1) TCR, with (middle) or without (right) Treg activation. (B) Tregs were isolated from adult peripheral blood and transduced to express 
glutamic acid decarboxylase (GAD) 4.13 TCR. Transduced Tregs were sorted, labeled with cell proliferation dye (CPD) eFluor670, and plated in decreasing 
proportions with GAD 4.13 TCR transduced CD4+ responder T cells (Tresp) (Ag-specific) or MART-1 transduced CD8+ Tresp (Bystander) stained with cell trace violet 
(CTV) dye. For Ag-specific suppression, GAD 4.13 Tresp and Treg were activated with cognate GAD555–567 peptide presented by CD3-depleted peripheral blood 
mononuclear cell (PBMC) from an HLA-DR4 individual. For bystander suppression, MART-1 CD8+ Tresp and GAD 4.13 Tregs were activated with Melan-A27–35 with 
or without GAD555–567 peptide, again presented by CD3-depleted PBMC from an HLA-DR4 individual. Cell proliferation was evaluated via dye dilution for Tresp (top) 
and Tregs (bottom). Tresp proliferation decreased as the Treg to Tresp ratio increased only when Tregs were activated, and suppression was most effective when 
Treg activation was antigen-specific. Unactivated Tregs exhibited little to no proliferation. (c) Suppression was evaluated by Tresp division index (left) and percent (%) 
suppression (right). Tresp division index was significantly lower and percent suppression of Tresp proliferation was significantly greater in antigen-specific settings 
(Ag-specific, black) followed by bystander suppression when Tregs were activated (red). Two-way analysis of variance (ANOVA) (*P < 0.05, ***P < 0.001, 
****P < 0.0001).
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A B
FigUre 5 | High-avidity T-cell receptor (TCR) activation augments regulatory T-cell (Treg) suppression. (a) Tregs expressing the high-avidity GAD555–567-reactive  
R164 TCR (left) or the low-avidity GAD555–567-reactive 4.13 TCR (right) were activated with their cognate antigen. Activated Tregs were plated in decreasing 
proportions with Tresp expressing the R164 TCR and stained with cell trace violet (CTV) dye as indicated in the figure. Tresp proliferation was evaluated via dye 
dilution. Both Treg clones were able to suppress Tresp proliferation at 1:1 cell ratio, but R164 Tregs were more effective in suppressing Tresp proliferation at lower 
ratios (1/2:1–1/16:1). (B) Both Tresp proliferation and Treg suppression were normalized to the reporter enhanced green fluorescent protein (eGFP) mean 
fluorescence intensity (MFI) to control for potential variation in TCR expression levels. The Tresp division index (left) was significantly lower and percent (%) 
suppression (right) based on replication index was significantly greater for suppression assays using high-avidity R164 Tregs (green) compared with 4.13 Tregs (blue).
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mechanism that required Treg activation. Interestingly, when the 
high-avidity R164 or lower avidity 4.13 Treg avatars were cultured 
with R164 CD4+ Tresp in the presence of GAD555–567 peptide pre-
sented by CD3-depleted HLA-DRB1*04:01/HLA-A*02:01 APCs, 
R164 TCR were significantly more suppressive. This suggests 
that Treg TCR avidity affects suppressive ability and importantly, 
that the optimal avidity of TCR or CAR signals may be required 
for effective Treg avatar cellular therapy. Importantly, however, 
there is the potential for heterologous TCR chain pairing with 
the endogenous receptors, and further experiments are needed 
to empirically determine this for each receptor. Recent develop-
ments in gene editing technologies could be used to correct for 
this potential caveat. Specifically, knockout of endogenous TCR 
α- and β-chains via CRISPR/Cas9, silencing of endogenous 
TCR via shRNA with expression of a codon optimized de novo 
TCR, or the domain-swap approach described by Bethune et al. 
(41) could be applied.
Although preproinsulin (PPI) and alternative forms of this 
antigen (e.g., hybrid insulin peptides, alternative mRNA tran-
scripts) (42, 43) are considered key type 1 diabetes autoantigens, 
we anticipate continued expression of cognate antigen will be 
imperative for Treg survival and trafficking to the target organ 
(15, 44). Hence, we focused our efforts on the development of 
Tregs against GAD65, which exhibits a high autoantigen density 
in T1D (45) and is the target of persistent autoimmunity, as 
evidenced by maintenance of autoantibodies (46). We anticipate 
that adoptive cell therapy with GAD-specific Tregs will lead 
to bystander suppression and infectious tolerance (47) with 
the hope for inducing long-term antigen-specific tolerance to 
GAD as well as other β-cell antigens. A recent report by Hull 
et  al. described the generation and in  vitro characterization of 
peripheral blood-derived human Tregs expressing TCRs specific 
for insulinoma-associated protein-2 (IA-2) and insulin (48). 
Although the authors did not conduct functional comparisons of 
TCR avidity, in vivo investigations of these and the GAD-specific 
clones generated herein are certainly warranted to determine the 
optimal clone(s) for tolerogenic cell therapy as we move forward 
toward clinical testing.
Chimeric antigen receptor (CAR) Treg therapy should also 
be considered given the promising outcomes observed from 
CAR effector T cells in cancer immunotherapy (49, 50). CAR 
Treg therapy could be particularly advantageous given that CAR 
T cells are not constrained by HLA restriction, hence, offering the 
opportunity for off-the-shelf clinical utility. However, the need 
for surface expression of the target antigen on islets or β-cells 
represents a clear limitation compared with TCR gene transfer, 
which allows for recognition of intracellular antigens in the 
context of class II HLA. An additional approach to potentially 
address this challenge could involve the use of a CD8-restricted 
TCR that functions independently of the CD8 co-receptor. In 
fact, this type of activity has been demonstrated previously 
with a high-affinity melanoma antigen tyrosinase-reactive TCR 
expressed by CD4+ T cells (20). Yet an additional approach could 
involve the identification of a CAR capable of recognizing an 
islet epitope in the context of HLA-A2, given the observation 
that beta cells hyperexpress class I HLA in settings of type 1 
diabetes (51).
RNA TCR or CAR gene transfer has been demonstrated as 
one potential approach to confer T-cell antigen-specificity (52), 
and could be further explored in the context of tolerogenic 
adoptive Treg therapy for type 1 diabetes. Specifically, mRNA 
encoding the TCR or a CAR of choice can be introduced to 
T cells via electroporation, thereby eliminating the need for LV 
TD and associated safety requirements. This approach would, of 
course, be transient with transgene expression lasting only a few 
days (53), but might be accomplished with multiple autologous 
dosings. Temporary transgene expression presents lower risk of 
off-target effects such as bystander suppression of anti-tumor or 
anti-infection immunity. However, lentivirus transduced Treg 
avatars likely offer greater potential for long-term efficacy in 
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clearing islet infiltration/inflammation and leading to persistent 
engraftment.
Importantly, adoptive cell therapy with polyclonal autologous 
peripheral blood Tregs has been demonstrated to be safe in Phase 
I clinical trials (26, 27). While we anticipate a similar safety profile 
with TCR transgenic Treg therapy, tolerogenic cell therapies 
always carry with them possible associations with increased risk 
of infection or cancer due to bystander suppression and infectious 
tolerance mechanisms. Thus, there is a need to perform Phase I 
safety studies and simultaneously, investigate co-transfection of 
suicide genes for inducible apoptosis of TCR transgenic Tregs—a 
biological “off-switch” (54).
We recently demonstrated that cryopreserved umbili-
cal cord blood Tregs (cryoCB Tregs) could be isolated and 
expanded efficiently while retaining their naïve phenotype as 
well as suppressive capacity (55). Beyond the possibility for 
polyclonal autologous cryoCB Treg therapy, these cells offer 
the potential to generate antigen-specific Treg avatars from 
precursors with an optimal naïve phenotype and without the 
need for a large-volume peripheral blood draw and leukapher-
esis, which is generally contraindicated in pediatric patients. 
This is a goal currently being pursued by our lab and others. 
Additional optimization, such as further genetic manipulation 
of TCR transgenic Tregs, could be implemented to correct 
intrinsic single-nucleotide polymorphisms (SNPs) with puta-
tive implications for Treg function and known associations with 
type 1 diabetes as identified by genome-wide association stud-
ies (GWAS) (56). Beyond this, there is potential for delivery 
of tissue repair factors directly to the pancreas via production 
by antigen-specific Tregs or via conjugation to the Treg sur-
face using poly lactic-co-glycolic acid (PLGA) nanoparticles 
(57–59). For these approaches to be successful, we expect that 
Treg survival in  vivo and trafficking to the target organ will 
depend largely upon TCR specificity. Hence, we anticipate the 
functional effects of TCR avidity on human Treg phenotype and 
function, as demonstrated herein, will be extremely important 
as we refine adoptive cell therapies to reverse autoimmunity in 
type 1 diabetes.
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FigUre s1 | Comparable regulatory T-cell (Treg) avatar suppression of 
polyclonal stimulated responder T cells (Tresp). (a) Tregs were transduced with 
GAD-reactive TCR clones (R164 or 4.13) or remained untransduced (Mock) and 
cultured with autologous polyclonal Tresp cells in decreasing proportions for 
4 days with soluble anti-CD3 (2 µg/mL) and anti-CD28 (1 µg/mL) stimulation. 
Tresp proliferation was assessed by 3H-thymidine incorporation (left), and the 
percent suppression was determined by upon Tresp division index relative to the 
proliferation of Tresp when no Tregs were present (right). (B) IFN-γ production by 
polyclonal T cells was inhibited by Treg cells with or without TCR transduction. 
The levels of IFN-γ were measured from the supernatant by ELISA.
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